 |
Programme
Tuesday, February 2, 2010 | Wednesday, February 3, 2010 | Thursday, February 4, 2010
Tuesday, February 2, 2010
08h00 - 08h40 Registration
08h40 - 08h45 Opening remarks, S.E. Papapoulos
08h45 - 10h45 Discussion leader J.A. Kanis
08h45 - 09h30 Bone structure, function and strength, M.L. Bouxsein
▪ organization and composition of bone
▪ bone modeling and remodeling
▪ bone cells
▪ overview of histomorphometry
▪ determinants of bone strength
09h30 - 10h15 Pathophysiology of bone loss, R. Rizzoli
▪ bone growth and bone loss
▪ changes in microarchitecture
▪ molecular mechanisms
▪ hormonal regulation
▪ nutritional influence
▪ roles of cytokines
10h15 - 10h45 Definition, epidemiology and social aspects of osteoporosis, J.A. Kanis
▪ the clinical picture of patients with osteoporotic fractures
▪ pattern of fracture incidence with age and sex
▪ morbidity and mortality related to fractures
10h45 - 11h15 Coffee break
11h15 - 12.45 Discussion leader M.L. Bouxsein
11h15 - 11h45 Measurement of bone mass by DXA, R. Rizzoli
▪ precision and accuracy, technical issues
▪ lumbar spine, hip: which site to measure for which patient for diagnosis and monitoring
▪ total body bone mineral and soft tissue measurement: assessment of fat and lean body mass, application to clinical trials
11h45 - 12h15 Biochemical markers of bone turnover, M.R. McClung
▪ markers of formation and resorption
▪ advantages and limitations of markers
▪ technical and practical aspects of assays
▪ markers in phase I to phase III trials of anti-osteoporotic agents
▪ role of markers in the management of the osteoporosis patient
▪ markers of bone quality
12h15 - 12h45 New imaging techniques for assessing bone quality and strength, M.L. Bouxsein
▪ QCT
▪ high resolution MRI and pQCT to assess microarchitecture
▪ finite-element analysis
▪ use in clinical practice
▪ use in clinical trials
12h45 - 14h00 Lunch / Meet-the-Professor
14h00 - 16h00 Discussion leader M.R. McClung
14h00 - 14h30 What is an osteoporotic fracture?, C. Cooper
▪ high/low energy fractures
▪ relationship to BMD and gradients of risk
▪ vertebral deformities: what is normal and abnormal?
▪ which technique of vertebral morphometry to use for clinical trials in osteoporosis?
▪ clinical relevance of vertebral deformities
▪ underdiagnosis of vertebral deformities
▪ role of DXA
14h30 - 15h00 Assessment of fracture risk, J.A. Kanis
▪ validity of risk factors
▪ meta-analysis of risk factors
▪ fracture probability
15h00 - 15h30 Biomechanics of age-related fractures, M.L. Bouxsein
▪ interaction between skeletal loading and fracture etiology
▪ implications for fracture prevention strategies
15h30 - 16h00 Roundtable: Diagnostic tools and strategies for osteoporosis
J.A. Kanis (chairman), M.L. Bouxsein, R. Rizzoli
16h00 - 16h30 Coffee break
16h30 - 18h00 Discussion leader E.V. McCloskey
16h30 - 17h00 Nonpharmacological management of osteoporosis, R. Rizzoli
▪ exercise
▪ nutrition
▪ rehabilitation
▪ prevention of falls
▪ kyphoplasty/vertebroplasty
▪ specific measures in the elderly
17h00 - 17h30 Osteoporosis in men, M.R. McClung
▪ fracture incidence in males
▪ pathogenesis
▪ diagnosis threshold for BMD
▪ treatment
17h30 - 18h00 Corticosteroid-induced osteoporosis, S. Boonen
▪ effect of corticosteroids on bone, intestine and kidney
▪ epidemiology of corticosteroid-induced fractures
▪ prevention and treatment: what really works?
▪ recommendations to prevent corticosteroid-induced fractures
Wednesday, February 3, 2010
08h30 - 10h00 Discussion leader C. Cooper
08h30 - 08h45 What is the International Osteoporosis Foundation? P. McKenney
08h45 - 09h15 Calcium, vitamin D and its metabolites in osteoporosis, S. Boonen
▪ calcium and vitamin D insufficiency as key determinants of fracture risk
▪ calcium and fracture risk
▪ definition, epidemiology and consequences of vitamin D deficiency
▪ which vitamin D and how much to take?
▪ the role of vitamin D supplementation in the elderly
▪ clinical trials of vitamin D derivatives in osteoporosis: a critical review
09h15 - 10h00 Anabolic bone agents, J.Y. Reginster
▪ the role of PTH in the treatment of osteoporosis: effects on bone mass (trabecular and cortical bone), bone turnover and fractures
▪ the role of strontium ranelate in the treatment of osteoporosis: effects
on bone mass (trabecular and cortical bone), bone turnover and fractures
10h00 - 10h30 Roundtable: What is the role of general health program (including exercise) and of intervention on peak bone mass for the prevention of osteoporosis?
R. Rizzoli (chairman), M.R. McClung, S. Boonen
10h30 - 11h00 Coffee break
11h00 - 12.45 Discussion leader S.E. Papapoulos
11h00 - 11h30 Hormone replacement therapy, C. Cooper
▪ which estrogen and progestin to use?
▪ effects on bone mass and fractures
▪ nonskeletal effects (coronary heart disease, breast cancer, Alzheimer)
11h30 - 12h15 Clinical use of SERMs and other estrogen analogs, E.V. McCloskey
▪ SERMs
- concept of mechanism of action
- effects on bone loss and fractures
- effects on lipid metabolism and cardiovascular system
- safety profile including breast and endometrium
▪ other estrogen-like substances
12h15 - 12h45 Roundtable: Hormonal intervention in osteoporosis
C. Cooper (chairman), J.A. Kanis, E.V. McCloskey
12h45 - 14h15 Lunch / Meet-the-Professor
14h15 - 15h45 Discussion leader R. Rizzoli
14h15 - 14h35 Bisphosphonates: pharmacology and safety, S.E. Papapoulos
▪ pharmacology, pharmacokinetics, toxicology
▪ safety of bisphosphonates
14h35 - 15h15 Clinical use of bisphosphonates in postmenopausal osteoporosis, E.V. McCloskey
▪ critical review of clinical trials
▪ efficacy on vertebral and nonvertebral fractures
▪ intermittent bisphosphonates
15h15 - 15h45 Other antiresorptive drugs and combined therapy, J.Y. Reginster
▪ calcitonin
▪ denosumab
▪ combination/sequential therapy of antiresorptive and bone forming agents
15h45 - 16h15 Roundtable: Nonhormonal intervention in osteoporosis
S.E. Papapoulos (chairman), E.V. McCloskey, J.Y. Reginster
16h15 - 16h45 Coffee break
16h45 - 17h45 Discussion leader S. Boonen
16h45 - 17h15 Perspectives in the treatment of osteoporosis, S.E. Papapoulos
▪ future antiresorptives
▪ future anabolics
17h15 - 17h45 Tumoral bone disease, E.V. McCloskey
▪ pathophysiology of bone metastases
▪ pathogenesis of tumoral hypercalcemia of malignancy
▪ role of adjuvant therapy with inhibitors of bone resorption
Thursday, February 4, 2010
08h30 - 09h30 Discusson leader W.H. Dere
08h30 - 09h00 Clinical guidelines for the diagnosis and treatment of osteoporosis, J.A. Kanis
▪ diagnostic thresholds and strategies (WHO report)
▪ therapeutic strategies
▪ IOF vs. NOF guidelines
▪ health economic implications
09h00 - 09h30 Design of intervention studies in osteoporosis, S.E. Papapoulos
▪ which control group: placebo or reference treatment?
▪ clinical criteria for selection of patients
▪ choice of endpoints in preventive and curative treatment trials
▪ sample size and power for comparing two or more treatments (type I, II and III error)
▪ good clinical practice
09h30 - 12h00 Discussion leader J.Y. Reginster
09h30 - 10h15 Health economics in the context of osteoporosis, W.H. Dere
▪ the cost/benefit ratio of treatment
▪ the economical impact of targeting intervention to patients with low bone mass
▪ economical evaluation of new drugs: methodology and endpoints
10h15 - 10h45 Coffee break
10h45 - 11h30 Registration of new drugs for osteoporosis, W.H. Dere and J.Y. Reginster
- FDA guidelines
- CHMP guidelines
▪ registration requirements: which criteria for efficacy?
▪ U.S. compared to European guidelines
11h30 - 12h00 Development of a new drug in osteoporosis: from bench to marketing, W.H. Dere
12h00 - 12h10 Closing remarks, S.E. Papapoulos
